CalciMedica (NASDAQ: CALC) grants CSO 65,124 options at $0.585

Rhea-AI Filing Summary

CalciMedica, Inc. reported that Chief Scientific Officer Kenneth A. Stauderman received an employee stock option grant for 65,124 shares of common stock at an exercise price of $0.585 per share. The option expires on April 4, 2036.

Beginning April 1, 2026, 1/48 of the option vests in equal monthly installments over four years. Vesting will not begin until a Form S-8 is filed covering shares automatically added on January 1, 2026 under the company’s 2023 Equity Incentive Plan evergreen provision.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Stauderman Kenneth A.

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	65,124	$0.00	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 65,124 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 65,124 options Exercise price: $0.585 per share Total options after grant: 65,124 options +3 more

6 metrics

Option grant size 65,124 options Employee stock option award to CSO

Exercise price $0.585 per share Strike price for option grant

Total options after grant 65,124 options Total derivative holdings following transaction

Option expiration April 4, 2036 Final date to exercise options

Vesting commencement April 1, 2026 Start of 1/48 monthly vesting schedule

Vesting schedule fraction 1/48 monthly Equal monthly vesting over four years

Key Terms

Employee Stock Option, Exercise price, 2023 Equity Incentive Plan, evergreen provision, +1 more

5 terms

Employee Stock Option financial

"security_title: "Employee Stock Option (Right to Buy)""

An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.

Exercise price financial

"conversion_or_exercise_price: "0.5850" per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

2023 Equity Incentive Plan financial

"authorized for issuance under the Company's 2023 Equity Incentive Plan"

evergreen provision financial

"pursuant to an annual "evergreen" provision"

An evergreen provision is a clause in a financing or contract that automatically renews or replenishes the arrangement unless one party actively cancels it, like a subscription that keeps renewing each term. For investors it matters because it creates predictable, ongoing access to funding or ongoing contractual obligations — helping liquidity and planning — but can also hide long-term commitments or dilution risks if not reviewed.

Form S-8 regulatory

"until the filing of the Company's registration statement on Form S-8"

A Form S-8 is a U.S. Securities and Exchange Commission registration that lets a public company set aside shares for employee benefit plans and stock-based compensation. Think of it as opening a dedicated account that authorizes the company to issue or reserve stock for workers and directors; it matters to investors because it enables share dilution when those awards are granted or exercised and signals how management is compensated and incentivized.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stauderman Kenneth A.

(Last) (First) (Middle)

CALCIMEDICA, INC.

505 COAST S. BLVD. #307

(Street)

LA JOLLA CALIFORNIA 92037

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CalciMedica, Inc. [ CALC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$0.585	04/05/2025		A		65,124		(1)	04/04/2036	Common Stock	65,124	$0	65,124	D

Explanation of Responses:

1. Beginning April 1, 2026, 1/48th of the shares subject to the option vest in equal monthly installments over a four year period, provided, however, that no shares shall vest until the filing of the Company's registration statement on Form S-8 covering the shares of Common Stock that were automatically added to the shares authorized for issuance under the Company's 2023 Equity Incentive Plan on January 1, 2026 pursuant to an annual "evergreen" provision.

	/s/ John Dunn, Attorney-in-Fact	04/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CalciMedica (CALC) report for Kenneth A. Stauderman?

CalciMedica reported an employee stock option grant to Chief Scientific Officer Kenneth A. Stauderman for 65,124 shares of common stock. The options are part of executive compensation and give him the right to buy shares at a fixed exercise price in the future.

What are the key terms of the CalciMedica (CALC) stock option grant?

The grant covers 65,124 options with an exercise price of $0.585 per share and an expiration date of April 4, 2036. These options allow the holder to purchase CalciMedica common stock at that fixed price before expiration, subject to vesting.

How do the CalciMedica (CALC) options granted to the CSO vest?

Vesting begins on April 1, 2026, when 1/48 of the options start vesting in equal monthly installments over four years. This means the award becomes exercisable gradually, encouraging longer-term alignment between the executive and shareholders.

What condition must be met before the CalciMedica (CALC) options start vesting?

No shares under this option will vest until CalciMedica files a Form S-8 covering common stock automatically added on January 1, 2026 to the 2023 Equity Incentive Plan under its evergreen provision. This regulatory filing enables issuance of those plan shares.

Did the CalciMedica (CALC) Form 4 show any stock sales or purchases in the market?

The Form 4 shows a grant of employee stock options, not open-market stock purchases or sales. The transaction is coded as a grant or award, reflecting compensation rather than a discretionary buy or sell of existing CalciMedica shares.